Cargando…

Peg-Grafted Liposomes for L-Asparaginase Encapsulation

L-asparaginase (ASNase) is an important biological drug used to treat Acute Lymphoblastic Leukemia (ALL). It catalyzes the hydrolysis of L-asparagine (Asn) in the bloodstream and, since ALL cells cannot synthesize Asn, protein synthesis is impaired leading to apoptosis. Despite its therapeutic impor...

Descripción completa

Detalles Bibliográficos
Autores principales: de Souza Guimarães, Marina, Cachumba, Jorge Javier Muso, Bueno, Cecilia Zorzi, Torres-Obreque, Karin Mariana, Lara, Grace Verónica Ruiz, Monteiro, Gisele, Barbosa, Leandro Ramos Souza, Pessoa, Adalberto, Rangel-Yagui, Carlota de Oliveira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503594/
https://www.ncbi.nlm.nih.gov/pubmed/36145567
http://dx.doi.org/10.3390/pharmaceutics14091819
_version_ 1784796002796961792
author de Souza Guimarães, Marina
Cachumba, Jorge Javier Muso
Bueno, Cecilia Zorzi
Torres-Obreque, Karin Mariana
Lara, Grace Verónica Ruiz
Monteiro, Gisele
Barbosa, Leandro Ramos Souza
Pessoa, Adalberto
Rangel-Yagui, Carlota de Oliveira
author_facet de Souza Guimarães, Marina
Cachumba, Jorge Javier Muso
Bueno, Cecilia Zorzi
Torres-Obreque, Karin Mariana
Lara, Grace Verónica Ruiz
Monteiro, Gisele
Barbosa, Leandro Ramos Souza
Pessoa, Adalberto
Rangel-Yagui, Carlota de Oliveira
author_sort de Souza Guimarães, Marina
collection PubMed
description L-asparaginase (ASNase) is an important biological drug used to treat Acute Lymphoblastic Leukemia (ALL). It catalyzes the hydrolysis of L-asparagine (Asn) in the bloodstream and, since ALL cells cannot synthesize Asn, protein synthesis is impaired leading to apoptosis. Despite its therapeutic importance, ASNase treatment is associated to side effects, mainly hypersensitivity and immunogenicity. Furthermore, degradation by plasma proteases and immunogenicity shortens the enzyme half-life. Encapsulation of ASNase in liposomes, nanostructures formed by the self-aggregation of phospholipids, is an attractive alternative to protect the enzyme from plasma proteases and enhance pharmacokinetics profile. In addition, PEGylation might prolong the in vivo circulation of liposomes owing to the spherical shielding conferred by the polyethylene (PEG) corona around the nanostructures. In this paper, ASNase was encapsulated in liposomal formulations composed by 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) or 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) containing or not different concentrations of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N [methoxy (polyethylene glycol)-2000] (DSPE-PEG). Nanostructures of approximately 142–202 nm of diameter and polydispersity index (PDI) of 0.069 to 0.190 were obtained and the vesicular shape confirmed by Transmission Electron Microscopy (TEM and cryo-TEM). The encapsulation efficiency (%EE) varied from 10% to 16%. All formulations presented activity in contact with ASNase substrate, indicating the liposomes permeability to Asn and/or enzyme adsorption at the nanostructures’ surface; the highest activity was observed for DMPC/DSPE-PEG 10%. Finally, we investigated the activity against the Molt 4 leukemic cell line and found a lower IC(50) for the DMPC/DSPE-PEG 10% formulation in comparison to the free enzyme, indicating our system could provide in vivo activity while protecting the enzyme from immune system recognition and proteases degradation.
format Online
Article
Text
id pubmed-9503594
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95035942022-09-24 Peg-Grafted Liposomes for L-Asparaginase Encapsulation de Souza Guimarães, Marina Cachumba, Jorge Javier Muso Bueno, Cecilia Zorzi Torres-Obreque, Karin Mariana Lara, Grace Verónica Ruiz Monteiro, Gisele Barbosa, Leandro Ramos Souza Pessoa, Adalberto Rangel-Yagui, Carlota de Oliveira Pharmaceutics Article L-asparaginase (ASNase) is an important biological drug used to treat Acute Lymphoblastic Leukemia (ALL). It catalyzes the hydrolysis of L-asparagine (Asn) in the bloodstream and, since ALL cells cannot synthesize Asn, protein synthesis is impaired leading to apoptosis. Despite its therapeutic importance, ASNase treatment is associated to side effects, mainly hypersensitivity and immunogenicity. Furthermore, degradation by plasma proteases and immunogenicity shortens the enzyme half-life. Encapsulation of ASNase in liposomes, nanostructures formed by the self-aggregation of phospholipids, is an attractive alternative to protect the enzyme from plasma proteases and enhance pharmacokinetics profile. In addition, PEGylation might prolong the in vivo circulation of liposomes owing to the spherical shielding conferred by the polyethylene (PEG) corona around the nanostructures. In this paper, ASNase was encapsulated in liposomal formulations composed by 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) or 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) containing or not different concentrations of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N [methoxy (polyethylene glycol)-2000] (DSPE-PEG). Nanostructures of approximately 142–202 nm of diameter and polydispersity index (PDI) of 0.069 to 0.190 were obtained and the vesicular shape confirmed by Transmission Electron Microscopy (TEM and cryo-TEM). The encapsulation efficiency (%EE) varied from 10% to 16%. All formulations presented activity in contact with ASNase substrate, indicating the liposomes permeability to Asn and/or enzyme adsorption at the nanostructures’ surface; the highest activity was observed for DMPC/DSPE-PEG 10%. Finally, we investigated the activity against the Molt 4 leukemic cell line and found a lower IC(50) for the DMPC/DSPE-PEG 10% formulation in comparison to the free enzyme, indicating our system could provide in vivo activity while protecting the enzyme from immune system recognition and proteases degradation. MDPI 2022-08-29 /pmc/articles/PMC9503594/ /pubmed/36145567 http://dx.doi.org/10.3390/pharmaceutics14091819 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
de Souza Guimarães, Marina
Cachumba, Jorge Javier Muso
Bueno, Cecilia Zorzi
Torres-Obreque, Karin Mariana
Lara, Grace Verónica Ruiz
Monteiro, Gisele
Barbosa, Leandro Ramos Souza
Pessoa, Adalberto
Rangel-Yagui, Carlota de Oliveira
Peg-Grafted Liposomes for L-Asparaginase Encapsulation
title Peg-Grafted Liposomes for L-Asparaginase Encapsulation
title_full Peg-Grafted Liposomes for L-Asparaginase Encapsulation
title_fullStr Peg-Grafted Liposomes for L-Asparaginase Encapsulation
title_full_unstemmed Peg-Grafted Liposomes for L-Asparaginase Encapsulation
title_short Peg-Grafted Liposomes for L-Asparaginase Encapsulation
title_sort peg-grafted liposomes for l-asparaginase encapsulation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503594/
https://www.ncbi.nlm.nih.gov/pubmed/36145567
http://dx.doi.org/10.3390/pharmaceutics14091819
work_keys_str_mv AT desouzaguimaraesmarina peggraftedliposomesforlasparaginaseencapsulation
AT cachumbajorgejaviermuso peggraftedliposomesforlasparaginaseencapsulation
AT buenoceciliazorzi peggraftedliposomesforlasparaginaseencapsulation
AT torresobrequekarinmariana peggraftedliposomesforlasparaginaseencapsulation
AT laragraceveronicaruiz peggraftedliposomesforlasparaginaseencapsulation
AT monteirogisele peggraftedliposomesforlasparaginaseencapsulation
AT barbosaleandroramossouza peggraftedliposomesforlasparaginaseencapsulation
AT pessoaadalberto peggraftedliposomesforlasparaginaseencapsulation
AT rangelyaguicarlotadeoliveira peggraftedliposomesforlasparaginaseencapsulation